AstraZeneca Signs Research Agreement With Shizuoka Prefecture Cancer Center
This article was originally published in PharmAsia News
Executive Summary
Osaka based AstraZeneca Japan signed an agreement Aug. 18 with the Shizuoka Prefecture Cancer Center to conduct basic research and clinical trials in an effort to develop new cancer drugs. According to the agreement, as the pharmaceutical company with the most cancer drugs in Japan, AstraZeneca will engage with center researchers starting from the drug candidate selection phase, and will use the feedback to speed up the developmental process of cancer drugs targeting Japanese and other Asian patients. It is the first such agreement between a global pharmaceutical company and a medical facility in Japan. (Click here for more - Japanese language) "The Shizuoka Prefecture Cancer Center Signs Development Agreement With Pharmaceutical Company" - Mainichi News (8/19/08)